Targets › AMPK
1 program from 1 company in 1 trial: 1 Phase 2; Other.
Catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. (UniProt, P54646)
Open in Phaseline: the race on AMPK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Intervene Immune | TRIIM Treatment Combination of somatropin (recombinant human growth hormone), metformin, and DHEA | GH1, AMPK | Phase 2 | Epigenetic Aging | – |
Epigenetic Aging (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.